Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM9KHZL)

Drug Name

Heparin Sodium Drug Info

Synonyms

(2S,3S,4R,5R,6R)-6-{[(2S,3S,4S,5R,6S)-6-{[(2R,3S,4S,5R)-2-carboxy-4,6-dihydroxy-5-(sulfooxy)oxan-3-yl]oxy}-2-hydroxy-4-(sulfomethyl)-5-(sulfooxy)oxan-3-yl]oxy}-3-{[(2R,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-[(sulfooxy)methyl]oxan-2-yl]oxy}-4,5-dihydroxyoxane-2-carboxylic acid; HepFlush; GTPL4214; CHEMBL526514; Heparin Sodium 10,000 Units And Dextrose 5% In Plastic Container

Indication

Disease Entry	ICD 11	Status	REF
Coagulation defect	3B10.0	Approved	[1]
Deep vein thrombosis	BD71	Approved	[2]

Therapeutic Class

Cardiovascular Agents

Cross-matching ID

PubChem CID: 92044406
TTD Drug ID: DM9KHZL

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Antithrombin-III (ATIII)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ardeparin	DMYRX8B	Deep vein thrombosis	BD71	Approved	[4]
Heparin Calcium	DMEVXY6	Coagulation defect	3B10.0	Approved	[4]
Sulodexide	DMNUC42	Tinnitus	MC41	Approved	[5]
Unfractionated heparin	DMCWM03	Thrombosis	DB61-GB90	Phase 3	[6]
Heparin low molecular weight	DMGFULM	Thrombosis	DB61-GB90	Phase 3	[7]
KW-3357	DMP3GI2	Coagulation defect	3B10.0	Phase 3	[8]
O-desulfated heparin	DMJL4A7	Chronic obstructive pulmonary disease	CA22	Phase 2	[9]
M118	DML0I2Z	Acute coronary syndrome	BA41	Phase 2	[10]
PMX-60056	DMWT73D	Coagulation defect	3B10.0	Phase 2	[11]
MER-102	DME18UM	Thrombosis	DB61-GB90	Phase 1	[12]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Antithrombin-III (ATIII)	TT4QPUL	ANT3_HUMAN	Modulator	[3]

------------------------------------------------------------------------------------

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4214).
3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2632).
4	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
5	Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide. Med Res Rev. 1998 Jan;18(1):1-20.
6	Heparin with low affinity to antithrombin III inhibits the activation of prothrombin in normal plasma. Thromb Res. 1982 Nov 15;28(4):487-97.
7	Effects of low molecular weight heparin on a severely antithrombin III-decreased disseminated intravascular coagulation model in rabbits. Thromb Res. 1995 Dec 1;80(5):391-8.
8	Company report (kyowa-kirin)
9	Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase. J Clin Invest. 1981 Jan;67(1):223-8.
10	Clinical pipeline report, company report or official report of Momentapharma.
11	Parenteral Anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Correction in: Chest. 2013 August; 144(2): 721.
12	Clinical pipeline report, company report or official report of Merrion's GIPET technology.